Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00806754 · ClinicalTrials.gov registry record · Phase 4

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

A Phase 4 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 4
Development phase
340
Enrollment target

NCT00806754: Completed Phase 4 study, sponsored by AstraZeneca.

NCT00806754 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 340 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00806754, a Phase 4 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 4
Development phase
340 participants
Enrollment target

Study Summary

* The primary objective of this study is to evaluate the efficacy of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray versus ciclesonide nasal spray alone in patients (18 years or older) with perennial allergic rhinitis (PAR) not adequately controlled on an intranasal corticosteroid or antihistamine monotherapy * The secondary objective is to investigate the safety of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray

Interventions

  • DRUG Ciclesonide nasal spray + placebo Azelastine
  • DRUG Ciclesonide nasal spray + Azelastine

Trial Details

FieldValue
Enrollment Target 340 participants
Start Date 2006-11
Est. Completion 2007-08
Phase Phase 4
AstraZeneca

1,285 total trials

What the finished NCT00806754 record still lists

NCT00806754 is an interventional study that assigns participants to a tested intervention. The registered 340 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (34% lower).

The record links to 0 conditions, and to 2 interventions - of which Ciclesonide nasal spray + placebo Azelastine is the first listed.

NCT00806754 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00806754 about?

NCT00806754 is a clinical study titled "Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)". * The primary objective of this study is to evaluate the efficacy of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray versus ciclesonide nasal spray alone in patients (18 years or older) with perennial allergic rhinitis (PAR) not adequately controlled on an intran...

What is the current status of trial NCT00806754?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 340 participants. The study started on 2006-11. Estimated completion is 2007-08.

What interventions are being tested in trial NCT00806754?

The interventions under investigation include: Ciclesonide nasal spray + placebo Azelastine (DRUG), Ciclesonide nasal spray + Azelastine (DRUG).

Who is sponsoring clinical trial NCT00806754?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00806754's enrollment target sits among peer trials

340 246th of 2000 higher than 1,753 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04176172 · 340 participants · Phase 3

    Optimizing Tobacco Use Treatment for PLWHA

  • NCT04545424 · 340 participants · Phase 2

    Trial of Therapeutic Hypothermia in Patients With ARDS

  • NCT04806958 · 340 participants · NA

    The PulsePoint Study

  • NCT05323409 · 340 participants · NA

    Improving Comprehensive Care of Cancer Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00806754, the US trial registry maintained by the National Library of Medicine. NCT00806754 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.